GGHC
SGMO

Gilder Gagnon Howe & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27,882
Closed -$473K – 281
2018
Q3 		$473K Hold
27,882
– – ﹤0.01% 242
2018
Q2 		$396K Sell
27,882
-34
-0.1% -$565 ﹤0.01% 241
2018
Q1 		$530K Sell
27,916
-76
-0.3% -$1.63K 0.01% 245
2017
Q4 		$459K Sell
27,992
-2,931
-9% -$43.6K 0.01% 240
2017
Q3 		$464K Sell
30,923
-27,455
-47% -$304K 0.01% 223
2017
Q2 		$514K Buy
58,378
+28,802
+97% +$185K 0.01% 220
2017
Q1 		$154K Buy
+29,576
New +$119K ﹤0.01% 245

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gilder Gagnon Howe & Co's SGMO Position: Q4 2018 in Review

Gilder Gagnon Howe & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2018, closing a stake of 27,882 shares — an estimated $473K sold.

Gilder Gagnon Howe & Co first reported a position in SGMO in Q1 2017 and held it in 7 quarters. The position peaked at $530K in Q1 2018. 197 funds tracked by Wall St. Rank hold SGMO as of Q4 2018.

  • Gilder Gagnon Howe & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2018 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 27,882 SANGAMO THERAPEUTICS INC shares in Q4 2018, an estimated $473K.
  • Gilder Gagnon Howe & Co first reported a position in SANGAMO THERAPEUTICS INC in Q1 2017 and held it in 7 quarters.
  • Gilder Gagnon Howe & Co's SANGAMO THERAPEUTICS INC position peaked at $530K in Q1 2018.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2018.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2018, filed 14 Feb 2019.